Opinion|Videos|February 11, 2025
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
Author(s)Mark D. Tyson, II, MD, MPH
A panelist discusses how less frequent treatment administration schedules and simpler delivery requirements of newer gene therapies reduce clinic resource burden by minimizing staff time, equipment usage, and biosafety requirements, allowing for more efficient allocation of health care resources.
Advertisement
Episodes in this series
- How does the ability to administer treatments less frequently, once every 3 months, reduce the resource expenditure in your clinic (eg, staff time and equipment use, allocating more time to patients who need more intensive care or follow-up)?
- Newer gene therapies may not require specialized equipment, such as biosafety hoods, for administration. How does this ease the burden on clinics like yours (such as monotherapy, biosafety, no reconstitution or dilution required)?
Advertisement
Related to this article
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Advertisement
Advertisement
Trending on Urology Times
1
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5